Rapport Therapeutics, Inc. Common Stock (RAPP) - Stock Analysis
Last updated: Jun 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Rapport Therapeutics surged nearly 200% after strong Phase 2a trial results and secured $250 million in capital, supported by positive clinical data and recent dilution-driven volatility, combining compelling catalysts with technical strength to represent a hot idea in the near term.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Cash buffer ⢠Operating losses ⢠Weak FCF RAPP is very strong on liquidity and balance-sheet safety, but persistent losses, negative cash flow, and a stretched valuation keep the investment case weak.
Price Behavior
Key Price Behavior Insights: ⢠Support Holding ⢠Rally Rejection ⢠Mid-Range Drift Support Level: $34.40â$35.00 Resistance Level: $37.50â$39.71 RAPP remains under pressure over the last month, with $34.4â$35.0 support holding but repeated failures below $37.5â$39.7 keeping the short-term trend cautious.
Sentiment & News
Key News Insights: ⢠Loss Narrowing ⢠Earnings Beat ⢠Conference Outreach Rapport Therapeutics narrowed its quarterly loss versus expectations and last year while expanding investor outreach through upcoming healthcare conferences.
AI Summary
RAPP has moved from a survival story to a prove-it story: with a cash runway into 2029, the investment case now hinges on RAP-219 and the broader pipeline delivering clearly differentiated Phase 3/late-stage clinical data that can justify an already rich valuation, while any delay or underwhelming efficacy would likely compress the stock quickly.
Description
Rapport Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for central nervous system disorders. Its lead candidate, RAP-219, is a high-affinity inhibitor of TARPy8-containing AMPA receptors being evaluated for focal epilepsy and other CNS indications; the pipeline also includes an additional TARPy8 program and nicotinic acetylcholine receptor projects targeting chronic pain and hearing disorders. The company was incorporated in 2022, renamed from Precision Neuroscience NewCo in October 2022, and is based in Boston, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 15 | Sep 22 | RAPP | Rapport Therapeutics, Inc. Common Stock | Rapport Therapeutics surged nearly 200% after strong Phase 2a trial results and secured $250 million in capital, supported by positive clinical data and recent dilution-driven volatility, combining compelling catalysts with technical strength to represent a hot idea in the near term. | Closed | +5.6% |